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Abstract
Objectives
Corneal confocal microscopy (CCM) is a rapid, non-invasive, reproducible technique that
quantifies small nerve fibres. We have compared the diagnostic capability of CCM against a
range of established measures of nerve damage in patients with diabetic neuropathy.
Methods
In this cross sectional study, thirty subjects with Type 1 diabetes without neuropathy
(T1DM), thirty one T1DM subjects with neuropathy (DSPN) and twenty seven non-diabetic
healthy control subjects underwent detailed assessment of neuropathic symptoms and neu-
rologic deficits, quantitative sensory testing (QST), electrophysiology, skin biopsy and cor-
neal confocal microscopy (CCM).
Results
Subjects with DSPN were older (C vs T1DM vs DSPN: 41.0±14.9 vs 38.8±12.5 vs 53.3
±11.9, P = 0.0002), had a longer duration of diabetes (P<0.0001), lower eGFR (P = 0.006)
and higher albumin-creatinine ratio (P = 0.03) with no significant difference for HbA1c, BMI,
lipids and blood pressure. Patients with DSPN were representative of subjects with diabetic
neuropathy with clinical signs and symptoms of neuropathy and greater neuropathy deficits
quantified by QST, electrophysiology, intra-epidermal nerve fibre density and CCM. Corneal
nerve fibre density (CNFD) (Spearman’s Rho = 0.60 P<0.0001) and IENFD (Spearman’s
Rho = 0.56 P<0.0001) were comparable when correlated with peroneal nerve conduction
velocity. For the diagnosis of diabetic neuropathy the sensitivity for CNFD was 0.77 and spe-
cificity was 0.79 with an area under the ROC curve of 0.81. IENFD had a diagnostic sensitiv-
ity of 0.61, specificity of 0.80 and area under the ROC curve of 0.73.
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Conclusions
CCM is a valid accurate non-invasive method to identify small nerve fibre pathology and is
able to diagnose DPN.
Introduction
Diabetic peripheral neuropathy is a debilitating condition which may lead to pain, foot ulcera-
tion and eventual amputation. Therefore it is important to accurately diagnose both early dia-
betic neuropathy and those at high risk of foot ulceration [1]. A series of recent detailed
studies have shown that the clinical neurological assessment has poor reproducibility [2],
quantitative sensory testing (QST) showed good reproducibility, but remains subjective [3].
Nerve conduction studies are advocated as an essential component for the diagnosis of diabetic
neuropathy [4], however, small nerve fibres are the earliest to degenerate [5] and regenerate
[6] and indeed are central to the genesis of pain and development of foot ulceration [7].
In 2005 the European Federation of Neurological Societies published guidelines on the use
of skin biopsy in the diagnosis of peripheral neuropathies [8] and more recently the value of
the technique has been further emphasized [9]. Currently, skin biopsy with an assessment of
intra-epidermal nerve fibres (IENF) is considered the gold standard for the evaluation of small
fibre neuropathy and has been advocated for use as a measure of treatment response in clinical
trials [10]. Previously skin biopsy has demonstrated a good diagnostic ability of for small fibre
neuropathy [11–13]. Hence reproducible and reliable processing and accurate quantification
methods have been established for assessing IENF pathology against normative ranges [14].
However, despite being advocated as an endpoint in clinical trials of diabetic neuropathy there
is surprisingly scarce data which have established the diagnostic ability of skin biopsy for dia-
betic neuropathy [7]. Furthermore skin biopsy is invasive with a small but significant risk for
bleeding and infection and requires expertise in laboratory assessment.
CCM is a non-invasive ophthalmic application, which is rapid, non-invasive and readily
reproducible for quantifying small nerve fibres and has been shown to diagnose and track the
progression of diabetic neuropathy [15]. CCM has been shown to have reasonable diagnostic
utility in detecting DPN diagnosed using NDS [16] and has good reproducibility [17]. More
recently CCM has been shown to correlate with functional measures of small nerve fibre injury
[18] and indeed has been shown to precede an abnormality in neurophysiology in patients
with T1DM [19]. However, very few studies have directly assessed CCM against currently
accepted gold standard FDA approved methods such as skin biopsy, QST and nerve conduc-
tion studies in the diagnosis of diabetic neuropathy. We have therefore compared the ability of
CCM, skin biopsy and QST in the diagnosis of diabetic neuropathy using the Toronto criteria
for definite diabetic neuropathy (presence of an abnormality of nerve conduction and a symp-
tom or symptoms or a sign or signs of neuropathy) [4].
Research design and methods
Selection of patients
In this cross sectional study, thirty subjects with Type 1 diabetes without neuropathy (T1DM)
(n = 30), thirty one T1DM subjects with neuropathy (DSPN) (n = 31) and twenty seven non-
diabetic healthy control subjects (Controls) (n = 27) were evaluated. Subjects were consecu-
tively assessed and were unselected. Subjects with a history of neurologic conditions, ocular
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trauma or previous ocular surgery were excluded. Subjects were assessed at the Wellcome
Trust Clinical Research Facility (Manchester) from March 2010 to May 2013 and were not
recruited base on symptomatology of painful neuropathy. The study population was recruited
from a consecutive series of participants defined by the selection criteria. Data collection was
planned prospectively. The study was approved by the North Manchester Research Ethics
committee, and written informed consent was obtained according to the Declaration of Hel-
sinki. Funding was provided by JDRF, this study was investigator led. All diagnostic tests were
carried out in the same set of visit(s) with neurophysiology occasionally carried out on set
days. Intervals between tests were minimal with no active intervention administered in this
study.
Definition of neuropathy
Diabetic neuropathy was defined according to the Toronto criteria by the presence of an
abnormality of nerve conduction and a symptom or symptoms or a sign or signs of neuropa-
thy [4]. Nerve conduction studies, were carried out by a consultant neurophysiologist.
Assessment of neuropathy
All patients and control subjects underwent a detailed evaluation of neurologic symptoms by a
qualified physician according to the neuropathy symptom profile (NSP), and the McGill VAS
was used to assess the severity of painful neuropathy. Clinical neurologic deficits were assessed
using the modified neuropathy disability score, which includes an evaluation of vibration, pin
prick, and temperature perception as well as the presence or absence of ankle reflexes. Quanti-
tative sensory testing included an assessment of the vibration perception threshold (VPT),
measured using a neurothesiometer (Horwell, Scientific Laboratory Supplies, Wilford, Not-
tingham, U.K.), cold sensation (CST) (Aδ fibres) and warm sensation (WST) (c fibres) thresh-
olds using the method of limits with the MEDOC TSA II (Medoc, Ramat Vishay, Israel) on
the dorsum of the left foot. CASE IV was used to measure the heart rate response to deep
breathing (HR-DVB) over two 8-cycle breathing series separated by a 5-min period of normal
breathing. Electro-diagnostic studies were undertaken using a Dante “Key point” system
(Dante Dynamics, Bristol, U.K.) equipped with a DISA temperature regulator to keep limb
temperature constantly between 32˚C and 35˚C. Peroneal motor and sural sensory nerves
were assessed in the right lower limb by a consultant neurophysiologist. The motor study was
performed using silver- silver chloride surface electrodes at standardized sites defined by ana-
tomical landmarks, and recordings for the sural nerve were taken using antidromic stimula-
tion over a distance of 100 mm. Neuropathy status of the index subject were unknown at the
time of the above assessments.
Corneal confocal microscopy
Patients underwent examination with the Heidelberg retina tomography III in vivo corneal
confocal microscope employing our established methodology for image acquisition [20] by
two qualified optometrists (INP and MT) and only one optometrist (INP) undertook analysis
of corneal nerve morphology. We have previously shown good intra- and inter-observer
repeatability for quantification of corneal nerve morphology using CCM [17]. Several scans of
the entire depth of the cornea were recorded by turning the fine focus of the objective lens
backward and forward for ~2 min using the section mode, which enables manual acquisition
and storage of single images of all corneal layers. This provides en face two-dimensional
images with a lateral resolution of ~2 mm/pixel and final image size of 400 x 400 pixels of the
sub-basal nerve plexus of the cornea from each patient and control subject. Each sub-basal
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nerve fibre bundle contains unmyelinated fibres, which run parallel to Bowman’s layer before
dividing and terminating as individual axons underneath the surface epithelium. Five images
per patient from the centre of the cornea were selected and examined in a masked and rando-
mized fashion [21]. Three corneal nerve parameters were quantified: 1) CNFD, the total num-
ber of major nerves per square millimetre of corneal tissue (no.mm2); 2) corneal nerve branch
density (CNBD), the number of branches emanating from all major nerve trunks per square
millimetre of corneal tissue (no.mm2); and 3) corneal nerve fibre length (CNFL), the total
length of all nerve fibres and branches (mm/mm2) within the area of corneal tissue. Only one
healthy control and one subject with diabetes did not complete CCM assessment in this study.
Quantification of corneal nerve parameters was undertaken in a blinded fashion.
Skin biopsy and immunohistochemistry
A sub-cohort of participants underwent a 3-mm punch skin biopsy from the dorsum of the foot;
2 cm above the second metatarsal head after local anaesthesia (1% lidocaine). The biopsy site
was closed using Steristrips, and the specimen was immediately fixed in PBS-buffered 4% paraf-
ormaldehyde for 18–24 h, washed—in Tris-buffered saline, cryoprotected in sucrose, frozen in
liquid nitrogen and stored at -80˚C- and subsequently cut into 50-μm sections on a cryostat
microtome. Five floating sections per subject were immunostained for PGP9.5 neuronal marker.
Non-specific protein binding and endogenous peroxidase activity were blocked by incubation in
5% goat serum and 0.3% hydrogen peroxide, respectively. The anti-PGP9.5 antibody (EMD
Milipore, Billerica, MA, USA) was followed first by goat anti-rabbit IgG and then by HRP-Strep-
tavidin (both diluted 1:1000, both from Vector Laboratories, Peterborough, UK). Nerve fibres
were visualised by SG chromogen (Vector Laboratories). Intraepidermal nerve fibre density
(IENFD) was calculated as the number of nerve fibres crossing the basement membrane of the
epidermis and expressed per millimetre length of epidermis. Analysis of the IENF was con-
ducted in a blind fashion by two assessors and all subjects completed skin biopsy assessment.
Statistical analysis
Statistical analyses were undertaken on Statsdirect (Statsdirect, Cheshire, UK). The data are
expressed as Mean ± standard deviation (SD). ANOVA method or a non-parametric counter-
part, Kruskal-Wallis were used to assess differences between groups depending on normality
of the data. The Mann-Whitney U test was used to compare T1DM with DSPN for the dura-
tion of diabetes. Chi squared analyses were used to assess frequencies of gender, and ethnicity.
Overall the p value was maintained at 0.05 for multiple comparison tests (Bonferroni adjust-
ment or Conover-Inmann pairwise comparison). Spearman’s rank correlation was undertaken
for CNFD, CNBD, CNFL and IENFD versus NDS, McGill VAS, NSP, IENFD, thermal thresh-
olds, VPT, and nerve conduction studies. ROC curve analyses were used to define the Wil-
coxon estimate of area under ROC curve, optimal cut offs with associated sensitivity and
specificity for CCM parameters, IENFD, VPT and thermal thresholds. Positive predictive
value (PPV) and negative predictive value (NPV) were calculated for the three diagnostic mea-
sures, which had the greatest Wilcoxon estimate of area under the ROC curve.
Results
Demographics, metabolic and anthropometric assessment (Table 1)
We report no adverse events from this study. The participant demographics and metabolic
and anthropometric measurements in diabetic patients and control subjects are summarized
in Table 1. Patients with DSPN (53.3±11.9) were significantly older than controls (41.0±14.9
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years, P = 0.0008) and T1DM without DSPN (38.8±12.5, P<0.0001) and the duration of dia-
betes was greater in those with DSPN compared to those without DSPN (P<0.0001). HbA1c
(P<0.0001) was significantly higher in diabetic patients compared with control subjects with
no difference between T1DM patients with and without DSPN. Total cholesterol was signifi-
cantly lower in diabetic patients without (P = 0.006) and with (P = 0.002) DSPN compared to
control subjects. BMI, HDL, triglycerides, systolic and diastolic blood pressure were compar-
able between diabetic patients and control subjects. The estimated glomerular filtration rate
was lower in DSPN compared to T1DM without DSPN (P = 0.006), the Albumin-Creatinine
Ratio (ACR) was higher in DSPN compared to T1DM without DSPN (P = 0.03) and controls
(P = 0.004), although median values for controls, T1DM without DSPN and with DSPN were
all within the normal range.
Symptoms and deficits (Table 2)
Measures of sign(s) and symptoms of neuropathy are detailed in Table 2. The NDS was signifi-
cantly greater in patients with DSPN compared to control subjects (P<0.0001) and T1DM
without DSPN (P<0.0001), with no significant difference between controls and T1DM with-
out DSPN. The NSP was significantly higher in patients with DSPN (P<0.0001) compared to
Table 1. Participant demographics and metabolic parameters in control subjects and diabetic patients without (T1DM) and with (DSPN) neuropa-
thy, with statistically significant differences between groups.
C (n = 27) T1DM (n = 30) DSPN (n = 31) T1DM v DSPN
Age (years) 41.0±14.9 38.8±12.5 53.3±11.9 0.0002
Gender (Male) (%) 59 43 61 -
Ethnicity (White European) (%) 74 90 97 -
Aetiology of Diabetes (Type 1 DM) (%) - 100 100 NS
Duration of Diabetes (years) - 17.2±12.0 37.2±13.1 <0.0001
HbA1c (%) 5.5±0.3 8.0±1.3 8.5±1.5 NS
HbA1c (mmol/mol) 36.9±3.4 61.0±21.0 70.0±17.0 NS
BMI (kg/m2) 26.9±4.0 26.3±4.4 27.2±4.2 NS
T-CHL (mmol/l) 5.0±0.8 4.4±0.9 4.3±0.9 NS
HDL-C (mmol/l) 1.6±0.4 1.6±0.4 1.6±0.5 NS
Triglycerides 1.3±0.6 1.2±0.8 1.3±0.7 NS
Systolic BP (mmHg) 128±18 126±17 132±22 NS
Diastolic BP (mmHg) 70±10 71±10 72±9 NS
ACR (mg/mmol) 0.4±0.4 0.7±0.9 2.8±4.8 0.03
Median (IQR) 0.3 (0.2–0.4) 0.3 (0.2–0.5) 0.7 (0.2–2.7)
eGFR (ml/min/1.73) 85±7 90±3 80±18ƒ 0.006
Post Hoc Analyses
Age C vs T1DM (NS), C vs DSPN (P = 0.0008), T1DM vs DSPN (P<0.0001).
Gender Chi2 –P = 0.02
Ethnicity Chi2 –P<0.0001
HbA1c C vs T1DM (P<0.0001), C vs DSPN (P<0.0001), T1DM vs DSPN (NS).
T-CHL C vs T1DM (P = 0.006), C vs DSPN (P = 0.002), T1DM vs DSPN (NS).
ACR C vs T1DM (NS), C vs DSPN (P = 0.004), T1DM vs DSPN (P = 0.03).
eGFR C vs T1DM (NS), C vs DSPN (NS), T1DM vs DSPN (P = 0.006).
Table key
ACR–Albumin Creatinine Ratio, BMI–Body Mass Index, BP–Blood Pressure, C–Controls, estimated Glomerular Filtration Rate, HbA1c –Glycated
Haemoglobin A1c, T-CHL–Total Cholesterol, HDL–High Density Lipoprotein Cholesterol.
https://doi.org/10.1371/journal.pone.0180175.t001
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control subjects and T1DM without DSPN (P<0.0001). The McGill pain score and McGill
VAS were significantly greater in diabetic patients with DSPN compared with control subjects
(P = 0.001 and P = 0.0007 respectively) and patients with T1DM without DSPN (P = 0.01 and
P = 0.02 respectively). There were no differences in NDS, NSP, McGill pain score and VAS
between controls and T1DM without DSPN.
Neuropathy evaluation (Table 3)
Non–contact corneal aesthesiometery, small and large fibre neuropathy measures are high-
lighted in Table 3.
Electrophysiology. Peroneal nerve conduction velocity was significantly lower in DSPN
compared to controls (P<0.0001) and T1DM without DSPN (P<0.0001) and between T1DM
without DSN and controls (P<0.0001). Peroneal nerve amplitude was significantly lower
in DSPN compared with T1DM without DSPN (P<0.0001) and controls (P<0.0001). Sural
nerve conduction velocity and amplitude were significantly lower in DSPN (P<0.0001 and
P<0.0001 respectively) compared with control subjects and T1DM without DSPN (P<0.0001
and P<0.0001 respectively). Sural nerve conduction velocity was lower in T1DM without
DSPN compared to controls (P = 0.0008). However, values for sural and peroneal nerve con-
duction velocities and amplitudes were within the normal reference range in T1DM suggesting
that there was minimal large fibre deficit in this group.
Vibration perception and thermal thresholds. VPT was significantly greater in DSPN
compared to T1DM without DSPN (P<0.0001) and control subjects (P<0.0001). CST was sig-
nificantly greater in DSPN compared to T1DM without DSPN (P = 0.0007) and control sub-
jects (P<0.0001). WST was significantly greater in DSPN compared to T1DM without DSPN
(P = 0.0004) and controls (P<0.0001). There were no differences in VPT, CST and WST
between controls and T1DM without DSPN.
IENFD and CCM. Fig 1 shows skin biopsy specimens with highlighted IENF in controls,
T1DM without DSPN and with DSPN. IENFD was significantly reduced in subjects with DSPN
compared to T1DM without DSPN (P = 0.001) and control subjects (P<0.0001) and in T1DM
without DSPN compared to controls (P = 0.02). Red arrows point to intra-epidermal nerve fibres.
Table 2. Neuropathy symptoms and deficits in control subjects and diabetic patients without (T1DM) and with (DSPN) neuropathy, with statisti-
cally significant differences between groups.
C (n = 27) T1DM (n = 30) DSPN (n = 31) T1DM v DSPN
NDS (-/10) 0.4±0.8 1.2±2.0 4.6±3.3 <0.0001
Median (IQR) 0 (0–1) 0 (0–2) 5 (2–7)
NSP (-/38) 0.1±0.4 1.3±2.0 5.0±6.2 <0.0001
Median (IQR) 0 (0–0) 0 (0–2) 2.5 (0–6)
VAS (-/10cm) 0.2±1.0 1.0±2.3 3.3±3.8 0.01
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0)
McGill Pain score 0.1±0.4 1.9±6.5 4.2±6.5 0.02
Median (IQR) 0 (0–0) 0 (0–0) 2 (0–5)
Post Hoc Analyses
NDS: C vs T1DM (NS), C vs DSPN (P<0.0001), T1DM vs DSPN (P<0.0001)
NSP: C vs T1DM (NS), C vs DSPN (P<0.0001), T1DM vs DSPN (P<0.0001)
McGill VAS: C vs T1DM (NS), C vs DSPN (P = 0.001), T1DM vs DSPN (P = 0.01)
McGill Pain score: C vs T1DM (NS), C vs DSPN (P = 0.0007), T1DM vs DSPN (P = 0.02)
Table key
C–Controls, McGill VAS–McGill Visual Analogue Score, NDS–Neuropathy Disability Score, NSP–Neuropathy Symptom Profile.
https://doi.org/10.1371/journal.pone.0180175.t002
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Fig 2 shows CCM images with highlighted corneal nerves in controls, T1DM without
DSPN and with DSPN from the same subjects as in Fig 1. CNFD, CNBD and CNFL were sig-
nificantly lower in DSPN compared with both T1DM without DSPN (CNFD: P<0.0001,
CNBD: P = 0.02 and CNFL: P = 0.001) and controls (CNFD: P<0.0001, CNBD: P<0.0001 and
CNFL: P<0.0001). These parameters were also significantly lower in patients with T1DM
compared to controls (CNFD: P<0.0001, CNBD: P = 0.0008 and CNFL: P<0.0001) suggesting
early small fibre damage. Red arrows show corneal nerve branches and yellow arrows show
corneal nerve fibres.
Correlates of CCM & IENFD (Table 4)
To explore the relationship of CCM parameters and IENFD with other diagnostic modalities,
Spearman’s rank correlations of these measures were undertaken and are highlighted in
Table 4. The strongest correlation was between CNFD and peroneal motor nerve conduction
velocity (Rho = 0.60, P<0.0001). Other neurophysiology measures correlated well with CNFD
(peroneal nerve amplitude: Rho = 0.52 P<0.0001, sural nerve velocity: Rho = 0.52 P<0.0001,
Table 3. Small and large fibre tests of nerve structure and function in control subjects and diabetic patients without (T1DM) and with (DSPN) neu-
ropathy, with statistically significant differences between groups.
C (n = 27) T1DM (n = 30) DSPN (n = 31) T1DM v DSPN
NCCA (mBar) 0.5±0.3 0.8±0.7 1.3±2.6 NS
CNFD (no/mm2) 37.2±5.1 30.1±6.7 19.8±9.2 <0.0001
CNBD (no/mm2) 92.0±36.2 60.7±27.9 45.4±32.0 0.02
CNFL (mm/mm2) 26.6±3.8 21.5±4.8 15.8±7.0 0.001
IENFD (no/mm) 10.2±3.3 8.3±5.5 4.7±4.3 0.001
CST (˚C) 28.6±2.0 27.5±2.0 21.4±9.1 0.0007
WST(˚C) 36.4±2.0 38.1±3.4 41.8±4.5 0.0004
VPT (volts) 5.3±4.1 5.6±2.5 18.4±12.2 <0.0001
Sural SNCV (m/s) 50.6±2.0 47.1±4.1 39.4±6.1 <0.0001
Sural Amp (μV) 20.2±8.8 15.1±6.1 5.5±4.2 <0.0001
Peroneal MNCV (m/s) 49.2±3.7 45.5±2.2 35.4±8.6 <0.0001
Peroneal Amp (mV) 6.1±2.4 7.3±9.7 2.4±2.1 <0.0001
Post hoc analyses
CNFD: C vs T1DM (P<0.0001), C vs DSPN (P<0.0001), T1DM vs DSPN (P<0.0001)
CNBD: C vs T1DM (P = 0.0008), C vs DSPN (P<0.0001), T1DM vs DSPN (P = 0.02)
CNFL: C vs T1DM (P<0.0001), C vs DSPN (<0.0001), T1DM vs DSPN (P = 0.001)
IENFD: C vs T1DM (P = 0.02), C vs DSPN (P<0.0001), T1DM vs DSPN (P = 0.001)
CST: C vs T1DM (NS), C vs DSPN (P<0.0001), T1DM vs DSPN (P = 0.0007)
WST: C vs T1DM (NS), C vs DSPN (P<0.0001), T1DM vs DSPN (P = 0.0004)
VPT: C vs T1DM (NS), C vs DSPN (P<0.0001), T1DM vs DSPN (P<0.0001)
SNCV: C vs T1DM (P = 0.0008), C vs DSPN (P<0.0001), T1DM vs DSPN (P<0.0001)
SNAmp: C vs T1DM (NS), C vs DSPN (P<0.0001), T1DM vs DSPN (P<0.0001)
PMNCV: C vs T1DM (P<0.0001), C vs DSPN (P<0.0001), T1DM vs DSPN (P<0.0001)
PMNAmp: C vs T1DM (NS), C vs DSPN (P<0.0001), T1DM vs DSPN (P<0.0001)
Table key
C–Controls, CNFD–Corneal Nerve Fibre Density, CNBD–Corneal Nerve Branch Density, CNFL–Corneal Nerve Fibre Length, CST–Cold Sensation
Threshold, IENFD–Intra Epidermal Nerve Fibre Density, PMNAmp–Peroneal Motor Nerve Amplitude, PMNCV–Peroneal Motor Nerve Conduction Velocity,
SSNAmp–Sural Nerve Sensory Nerve Amplitude, SMNCV–Sural Motor Nerve Conduction Velocity VPT–Vibration Perception Threshold, WST–Warm
Sensation Threshold.
https://doi.org/10.1371/journal.pone.0180175.t003
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sural nerve amplitude: Rho = 0.48 P<0.0001). IENFD correlated less well (peroneal motor
nerve velocity Rho = 0.56 P<0.0001, peroneal nerve amplitude: Rho = 0.45 P<0.0001, sural
nerve velocity: Rho = 0.45 P<0.0001, sural nerve amplitude: Rho = 0.50 P<0.0001). Only a low
to moderate correlation (Rho = 0.3–0.49) was found between CCM parameters and IENFD
(CNFD: Rho = 0.33 P = 0.001, CNBD: Rho = 0.33 P = 0.003, CNFL: Rho = 0.32 P = 0.002).
However, both signs (NDS) and in particular symptoms (NSP and McGill visual analogue
score) correlated better with CNFD and IENFD.
Receiver-Operating Characteristic (ROC) analysis (Table 5, Fig 3)
To assess the diagnostic ability of small and large fibre tests including optimal cut offs, sensitiv-
ity and specificity, ROC analysis was undertaken for all measures of neuropathy and are high-
lighted in Table 5. As the definition of DSPN was based on the nerve conduction studies
(Toronto criteria for definite diabetic neuropathy [4]) we have used the ROC analysis for
Fig 1. A, B & C. Skin biopsy images of IENF in C, T1DM and DSPN.Red arrows point to intra-epidermal
nerve fibres.
https://doi.org/10.1371/journal.pone.0180175.g001
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peroneal motor nerve conduction velocity as the referent value for Wilcoxon estimate of area
under ROC curve = 0.98 (95% CI: 0.49–1), sensitivity = 0.94 (95% CI: 0.79–0.99) and specifi-
city = 1 (95% CI: 0.88–1). The Wilcoxon estimate of area under the ROC curve was greatest
Fig 2. A, B & C. CCM images in C, T1DM and DSPN. Red arrows show corneal nerve branches and yellow arrows show corneal nerve fibres.
https://doi.org/10.1371/journal.pone.0180175.g002
Table 4. Spearman’s rank correlation of CNFD, CNBD, CNFL and IENFD versus NDS, McGill VAS, NSP, IENFD, thermal thresholds, VPT and nerve
conduction studies.
CNFD CNBD CNFL IENFD
NDS (-/10) • Rho = -0.45
• P<0.0001
• Rho = -0.27
• P = 0.01
• Rho = -0.34
• P = 0.001
• Rho = -0.47
• P<0.0001
VAS(-/10cm) • Rho = -0.43
• P<0.0001
• Rho = -0.34
• P = 0.002
• Rho = -0.43
• P<0.0001
• Rho = -0.45
• P<0.0001
NSP (-/38) • Rho = -0.51
• P<0.0001
• Rho = -0.28
• P = 0.009
• Rho = -0.39
• P = 0.0002
• Rho = -0.51
• P<0.0001
IENFD (no/mm) • Rho = 0.33
• P = 0.001
• Rho = 0.31
• P = 0.003
• Rho = 0.32
• P = 0.002
• N/a
CST (˚C) • Rho = 0.37
• P = 0.0005
• Rho = 0.23
• P = 0.04
• Rho = 0.26
• P = 0.02
• Rho = 0.33
• P = 0.002
WST(˚C) • Rho = -0.39
• P = 0.0003
• Rho = -0.35
• P = 0.0009
• Rho = -0.33
• P = 0.002
• Rho = -0.52
• P<0.0001
VPT (volts) • Rho = -0.49
• P<0.0001
• Rho = -0.31
• P = 0.004
• Rho = -0.37
• P = 0.0004
• Rho = -0.47
• P<0.0001
SSNCV (m/s) • Rho = 0.52
• P<0.0001
• Rho = 0.40
• P = 0.0002
• Rho = 0.43
• P<0.0001
• Rho = 0.45
• P<0.0001
SSNAmp (μV) • Rho = 0.48
• P<0.0001
• Rho = 0.28
• P = 0.01
• Rho = 0.34
• P = 0.002
• Rho = 0.50
• P<0.0001
PMNCV (m/s) • Rho = 0.60
• P<0.0001
• Rho = 0.46
• P<0.0001
• Rho = 0.54
• P<0.0001
• Rho = 0.56
• P<0.0001
PMNAmp (mV) • Rho = 0.52
• P<0.0001
• ho = 0.40
• P = 0.0002
• Rho = 0.52
• P<0.0001
• Rho = 0.45
• P<0.0001
The strongest correlations are for CCM parameters and IENFD are highlighted in bold.
Table key
CNFD–Corneal Nerve Fibre Density, CNBD–Corneal Nerve Branch Density, CNFL–Corneal Nerve Fibre Length, CST–Cold Sensation Threshold, IENFD–
Intra Epidermal Nerve Fibre Density, NSP–Neuropathy Symptom Profile, PMNAmp–Peroneal Motor Nerve Amplitude, PMNCV–Peroneal Motor Nerve
Conduction Velocity, SSNAmp–Sural Nerve Sensory Nerve Amplitude, SMNCV–Sural Motor Nerve Conduction Velocity, VAS–McGill Visual Analogue
Score, VPT–Vibration Perception Threshold, WST–Warm Sensation Threshold.
https://doi.org/10.1371/journal.pone.0180175.t004
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for VPT at 0.85 with an optimal cut off of 13 volts, sensitivity of 0.67, specificity of 1, PPV of
1.0 and NPV 0.75. The small fibre test with the greatest Wilcoxon estimate of area under the
ROC curve was CNFD at 0.81 (Fig 3). The PPV and NPV for CNFD were 0.8 and 0.77 respec-
tively for a cut off of 25. IENFD had a lower Wilcoxon estimate of area under the ROC curve
at 0.73, which was similar to CNFL (0.74), CST (0.76) and WST (0.74). The PPV and NPV
Table 5. ROC analysis with area under the curve, optimal cut off and respective sensitivity and specificity with 95% confidence interval in T1DM
without DSPN versus DSPN for CNFD, CNBD, CNFL, IENFD, VPT, CST and WST.
Optimal Cut off AUC (95% CI) Sensitivity (95% CI) Specificity (95% CI)
CNFD (no/mm2) 25.0 • 0.81
• (0.47–1.0)
• 0.77
• (0.59–0.90)
• 0.79
• (0.60–0.92)
CNBD (no/mm2) 36.5 • 0.67
• (0.45–0.90)
• 0.58
• (0.39–0.75)
• 0.79
• (0.60–0.92)
CNFL (mm/mm2) 16.8 • 0.74
• (0.46–1.0)
• 0.61
• (0.42–0.78)
• 0.86
• (0.68–0.96)
IENFD (no/mm) 4.5 • 0.73
• (0.46–1.0)
• 0.61
• (0.42–0.78)
• 0.80
• (0.61–0.92)
VPT (Volts) 13 • 0.85
• (0.74–0.95)
• 0.67
• (0.47–0.83)
• 1
• (0.88–1)
CST (˚C) 24.7 • 0.76
• (0.46–1.0)
• 0.57
• (0.37–0.76)
• 0.89
• (0.72–0.98)
WST (˚C) 38.0 • 0.74
• (0.61–0.88)
• 0.86
• (0.67–0.96)
• 0.64
• (0.44–0.81)
Table key
CNFD–Corneal Nerve Fibre Density, CNBD–Corneal Nerve Branch Density, CNFL–Corneal Nerve Fibre Length, CST–Cold Sensation Threshold, IENFD–
Intra Epidermal Nerve Fibre Density, VPT–Vibration Perception Threshold, WST–Warm Sensation Threshold
https://doi.org/10.1371/journal.pone.0180175.t005
Fig 3. Receiver-operated characteristic (ROC) curves, based on the analysis of CNFD and IENFD in
T1DM without DSPN versus with DSPN. Black line represents CNFD and red line represents IENFD.
https://doi.org/10.1371/journal.pone.0180175.g003
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were also lower for IENFD at 0.76 and 0.67 respectively, for a cut off of 4.5 fibres/mm. Black
line represents CNFD and red line represents IENFD.
Sub-analyses of age matched groups (S1 Table)
As there was a significant difference in age between those with DSPN versus controls and
T1DM we have further sub-analysed age-matched subjects in controls, T1DM and DSPN
(Age, C: 46.2±14.0 vs T1DM 43.2±11.1 vs DSPN: 48.5±12.0 years, P = NS). The duration of
diabetes was longer, as expected in DSPN (31.1±12.6 years) compared to T1DM (20.2±12.3
years) (P = 0.01). These subgroups were representative of the complete cohort. There were
no significant differences between DSPN compared to T1DM for HbA1c, blood pressure or
lipids. Clinical signs and symptoms of neuropathy were greater in DSPN compared to T1DM.
There were significant differences between CNFD, CNFL, IENFD, VPT, CPT, WST, peroneal
nerve conduction velocity and amplitude and sural nerve conduction velocity and amplitude
between T1DM and DSPN. CNFD and IENFD had similar and significant correlations to
VPT, peroneal nerve conduction velocity and amplitude and sural nerve conduction velocity
and amplitude. These sub-analyses are included in the S1 Table. The Wilcoxon estimate of
area under the ROC curve was similar for CNFD, CNFL and IENFD (0.68, 0.69 and 0.68
respectively).
Discussion
There is a need for surrogate end points of diabetic neuropathy, which accurately detect early
disease, quantify disease progression and measure therapeutic response [22]. The current
‘gold’ standard for the diagnosis of neuropathy is neurophysiology, a robust measure that also
predicts foot ulceration and mortality in diabetes [23]. Other measures of neuropathy such as
neurological assessment are poorly reproducible [2], QST is subjective and more accurate
measures such as skin and nerve biopsy are invasive and require specialist analysis [4]. Small
fibre neuropathy has direct pathophysiological relevance to the main outcomes of pain and
foot ulceration [24] and therefore skin biopsy assessment of IENF has been proposed as a valid
measure of diabetic neuropathy [8]. Whilst skin biopsy detects early small nerve fibre damage
even when electrophysiology and QST are still normal [5], the use of this test in clinical trials is
limited by its invasive nature. CCM is a rapid and readily reiterative technique, which quanti-
fies small nerve fibres non-invasively [25–30]. The major findings of this study in relation to
the diagnostic ability of different small fibre tests in diabetic neuropathy are: 1) early subclini-
cal small nerve fibre loss can be detected by CCM and IENFD; 2) CNFD has a comparable
diagnostic utility to IENFD in the diagnosis of DSPN; 3) CNFD and IENFD have similar cor-
relation to nerve conduction studies.
Early intervention with improved glycaemic control in type 1 DM can lead to a durable
reduction in DPN [31]. Furthermore, the need for early evaluation of subclinical small fibre
neuropathy has been demonstrated by Smith et al [6] where lifestyle intervention with diet and
exercise in a pre-diabetic neuropathy group lead to cutaneous re-innervation and improved
pain. Previous studies have employed ROC curve analysis of IENFD at the distal leg and
shown a specificity of 95%-97% and sensitivity of 45%- 80% [14, 32] for small fibre neuropathy
but these studies were not specifically in patients with DPN. Recently Nebuchennykh et al [13]
in a study of patients with polyneuropathy from varying causes showed a sensitivity of 35%
and specificity of 95% using a cut off point of 6.7 fibres/mm for IENFD. In another study by
Vlckova-Moravcova et al [11], the diagnostic sensitivity for detecting neuropathy was 80% and
the specificity was 82% with an optimal IENFD cut off point of8.8 fibres/mm. Although,
ROC curve analysis is a standard and appropriate method for establishing diagnostic validity
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these studies were flawed as they assessed a disease group against a healthy control population
and thus sensitivities and specificities will be inappropriately high and the delineation of the
optimal cut off points inaccurate. The need to identify DPN in diabetic subjects should mean
that optimal cut off points for neuropathy should be based on data from a population of dia-
betic patients with and without neuropathy rather than a healthy control population versus
DPN. Therefore we have performed the present study in a population of diabetic patients with
and without neuropathy using the robust Toronto criteria and utilised a best fit ROC curve
analysis to derive optimal cut off points, sensitivities, and specificities to assess the diagnostic
validity of CCM measures and IENFD. ROC curve analysis in this study showed that IENFD
had a sensitivity of 61% and specificity of 80% at an optimal cut off point of 4.5 fibres/mm.
These diagnostic validity measures are clearly lower than in the current published literature
[11–13], but we believe are truly representative for DSPN as opposed to small fibre neuropathy
of other causes. Using exactly the same population and methods we show that CNFD has a
similar sensitivity of 77% and an almost identical specificity of 79% at an optimal cut off point
of 25.0 /mm.
Previous studies of IENFD have found either absent or weak correlations with nerve con-
duction studies [11] and sural nerve action potentials [14, 33, 34]. In the present study CNFD,
CNFL and IENFD showed a comparable correlation with peroneal motor nerve conduction
velocity and amplitude and sural nerve conduction velocity. These data support the study of
Shun et al [12] which showed a significant correlation between IENFD with sural nerve action
potential and warm sensation threshold. Thermal thresholds continue to be an important
reproducible psychophysical test in evaluating small nerve fibres [3, 35] and our data show
that the strongest correlation was indeed between IENFD and WST. For DPN, thermal thresh-
olds have previously shown a sensitivity which ranges from 36%-85% [6, 36, 37]. Sensitivities
reported in our study are 57% and 86% respectively for CST and WST. Furthermore, we have
shown negative correlations of WST with CCM measures and IENFD, confirming a previous
study [36]. Interestingly CNBD, CNFD and CNFL correlated with IENFD but the association
was a low one (Spearman’s Rho 0.33, 0.31 and 0.32 respectively). Although both CCM and
skin biopsy measure small nerve fibres, the sites of assessment are anatomically distinct. There
are no significant variations of IENFD calculated in adjacent sections from the same biopsy or
in adjacent biopsies from the same site [14]. However, differences in mean values exist for
IENFD between differing sites on the lower limb [14, 38] although no direct correlations have
been assessed between sites. Although DPN is considered a length dependent neuropathy,
recent studies suggest that lesions may occur in a proximal [39] multifocal fascicular pattern
[40]. In the current study, the groups are relatively small, and there are major differences
between the T1DM and DSPN groups with regard to age and diabetes duration although these
anthropometric differences are typically in keeping with risk factors for diabetic neuropathy.
Normative ranges for CNFD, CNFL and IENFD differ depending on the decade of life [41,
42]. Therefore, we have undertaken a further subgroup analyses by age-matching the subjects,
which shows comparable results for CNFD, CNFL and IENFD and is representative of the
overall study. However, the strength of this study is in the detailed quantification of large and
small nerve fibres and the accurate phenotyping of subjects with type 1 diabetes.
The current study provides a robust comparison between IENFD and CCM for the assess-
ment of DPN and confirms the results of previous studies [30, 43]. Both CNFD and IENFD
correlated well with clinical signs (NDS), and symptoms (McGill VAS and NSP). Furthermore,
CNFD and IENFD had similar diagnostic utility for DPN and comparable correlations with
electrophysiology. We believe these data provide a robust platform supporting the use of CCM
as a diagnostic test for human diabetic neuropathy.
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